According to Zacks, “PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. “
Other research analysts also recently issued reports about the stock. Credit Suisse Group AG boosted their price objective on shares of PTC Therapeutics to $15.00 in a research report on Tuesday. Wedbush reaffirmed a neutral rating and issued a $10.00 target price on shares of PTC Therapeutics in a research report on Tuesday. Citigroup Inc. upped their target price on shares of PTC Therapeutics from $8.00 to $9.00 and gave the stock a neutral rating in a research report on Monday, August 8th. JPMorgan Chase & Co. reduced their target price on shares of PTC Therapeutics from $18.00 to $17.00 and set a neutral rating on the stock in a research report on Friday, August 5th. Finally, Cowen and Company reaffirmed a hold rating on shares of PTC Therapeutics in a research report on Sunday, August 7th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $33.82.
Shares of PTC Therapeutics (NASDAQ:PTCT) traded up 1.51% on Tuesday, reaching $13.48. 131,507 shares of the company traded hands. PTC Therapeutics has a one year low of $5.27 and a one year high of $35.75. The stock’s market capitalization is $459.44 million. The stock’s 50 day moving average price is $10.19 and its 200-day moving average price is $7.97.
PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.27) by $0.13. The business had revenue of $15.40 million for the quarter, compared to the consensus estimate of $15.24 million. PTC Therapeutics had a negative net margin of 305.62% and a negative return on equity of 80.50%. The company’s quarterly revenue was up 150.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.14) EPS. Equities analysts forecast that PTC Therapeutics will post ($4.95) earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the stock. Bellevue Group AG acquired a new position in shares of PTC Therapeutics during the first quarter valued at $225,000. A.R.T. Advisors LLC acquired a new position in shares of PTC Therapeutics during the first quarter valued at $1,412,000. Sphera Funds Management LTD. boosted its position in shares of PTC Therapeutics by 278.7% in the first quarter. Sphera Funds Management LTD. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $1,610,000 after buying an additional 183,980 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in shares of PTC Therapeutics during the first quarter valued at $1,610,000. Finally, Wellington Management Group LLP boosted its position in shares of PTC Therapeutics by 48.4% in the first quarter. Wellington Management Group LLP now owns 4,699,733 shares of the biopharmaceutical company’s stock valued at $30,267,000 after buying an additional 1,532,712 shares during the period. Institutional investors and hedge funds own 83.32% of the company’s stock.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.